Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease

INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic agents for the treatment of type 2 diabetes mellitus, which lower blood glucose without causing severe hypoglycemia. However, the first cardiovascular (CV) safety trials have only recently reported their results...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuetz, Charles Andy, Ong, Siew Hwa, Blüher, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462855/
https://www.ncbi.nlm.nih.gov/pubmed/26089691
http://dx.doi.org/10.2147/CEOR.S75935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462855/
https://www.ncbi.nlm.nih.gov/pubmed/26089691
http://dx.doi.org/10.2147/CEOR.S75935

Ejemplares similares